Endo Plans Valstar Relaunch In Second Half
Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.
Bladder cancer drug, pulled from the market in 2002, became part of Endo’s portfolio when it acquired Indevus.